Identification of integrin drug targets for 17 solid tumor types

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Integrins regulate crucial cellular processes like migration, proliferation, and extracellular matrix remodeling.
• In solid tumors, integrins promote metastasis and angiogenesis, making them key targets for cancer therapy.
• Existing integrin antagonists show promise in halting tumor invasion and migration.

Purpose of the Study:

• To identify specific integrin heterodimers as potential therapeutic targets in 17 different solid tumors.
• To streamline the development of targeted integrin-based cancer therapeutics.
• To validate overexpressed integrin subunits using complementary data sources.

Main Methods:

• Computational analysis of The Cancer Genome Atlas (TCGA) gene expression data.
• Filtering of differentially expressed integrin subunits based on Fragments Per Kilobase of transcript per Million mapped reads (FPKM) levels.
• Validation of overexpressed integrin subunits by comparing RNA-sequencing (RNA-seq) data with immunohistochemistry (IHC) results.

Main Results:

• Identification of a set of differentially expressed integrin targets across 17 solid tumors.
• Pairing of overexpressed subunits into potential therapeutic heterodimeric targets.
• Validation of key overexpressed integrin subunits through IHC analysis.

Conclusions:

• The identified overexpressed integrins and their heterodimers represent promising targets for novel anti-cancer biologics and small molecule drugs.
• High-affinity ligands targeting these integrins can be utilized for targeted delivery of cancer therapeutics, nanotherapeutics, or imaging agents.
• This study provides a data-driven foundation for developing specific integrin-targeted cancer therapies.